CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb’s Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Un
Go back to CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb’s Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Un| Bristol-Myers Squibb (NYSE: BMY) | Delayed: 66.82 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $66.82 | 52 Week High | $77.12 | |||
| Open | $66.82 | 52 Week Low | $49.03 | |||
| Day High | $66.82 | P/E | 43.39 | |||
| Day Low | $66.82 | EPS | $1.54 | |||
| Volume | 1,992 | |||||
